Mechanisms of resistance and correlation between pre-treatment co-alterations and p-prognosis to osimertinib in chemo-naïve advanced non-small cell lung cancer.
Akihiro TamiyaMitsuo OsugaDaijiro HaradaShun-Ichi IsaYoshihiko TaniguchiKeiichi NakamuraYasuyuki MizumoriTsutomu ShinoharaHidetoshi YanaiKatsumi NakatomiMasahide OkiMasahide MoriTomohito KuwakoKoji YamazakiAtsuhisa TamuraMasahiko AndoYasuhiro KohPublished in: Lung cancer (Amsterdam, Netherlands) (2024)
MET amplification and PIK3CA mutation mechanisms underly resistance to osimertinib in patients. Patients with coexisting mutations or amplifications at baseline had shorter PFS and overall survival.
Keyphrases
- advanced non small cell lung cancer
- epidermal growth factor receptor
- small cell lung cancer
- end stage renal disease
- tyrosine kinase
- ejection fraction
- newly diagnosed
- chronic kidney disease
- prognostic factors
- photodynamic therapy
- squamous cell carcinoma
- combination therapy
- peritoneal dialysis
- radiation therapy
- smoking cessation
- patient reported
- free survival